Amylyx soars as blood sugar drug succeeds in late-stage trial
AMLX•AMLX•AMLX•AMLX•Up to the last close, the stock was up 77.4% year to date.
In the 78-patient trial, the drug achieved a 55% reduction in these low blood sugar episodes compared with a placebo during the 16-week study.
The company plans to submit the drug for U.S. regulatory approval by the end of this year, aiming for a potential commercial launch in 2027.
Shares of drug developer Amylyx Pharmaceuticals AMLX.O rose 42% to $30.45 premarket after the company said its drug avexitide met the main goal of improving post-bariatric hypoglycemia in a late-stage trial.
The condition is marked by dangerously low blood sugar levels in patients who have undergone weight-loss surgery.
